Use of biomarkers to guide decisions on adjuvant systemic therapy forwomenwith early-stage invasive breast cancer: American Society of clinical Oncology clinical practice guideline

Lyndsay N. Harris, Nofisat Ismaila, Lisa M. McShane, Fabrice Andre, Deborah E. Collyar, Ana M. Gonzalez-Angulo, Elizabeth H. Hammond, Nicole M. Kuderer, Minetta C Liu, Robert G. Mennel, Catherine Van Poznak, Robert C. Bast, Daniel F. Hayes

Research output: Contribution to journalArticle

330 Citations (Scopus)

Abstract

Purpose: To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. Methods: A literature search and prospectively defined study selection sought systematic reviews, metaanalyses, randomized controlled trials, prospective-retrospective studies, and prospective comparative observational studies published from 2006 through 2014. Outcomes of interest included overall survival and disease-free or recurrence-free survival. Expert panel members used informal consensus to develop evidence-based guideline recommendations. Results: The literature search identified 50 relevant studies. One randomized clinical trial and 18 prospectiveretrospective studies were found to have evaluated the clinical utility, as defined by the guideline, of specific biomarkers for guiding decisions on the need for adjuvant systemic therapy. No studies that met guideline criteria for clinical utility were found to guide choice of specific treatments or regimens. Recommendations: In addition to estrogen and progesterone receptors and human epidermal growth factor receptor 2, the panel found sufficient evidence of clinical utility for the biomarker assays Oncotype DX, EndoPredict, PAM50, Breast Cancer Index, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgroups of breast cancer. No biomarker except for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 was found to guide choices of specific treatment regimens. Treatment decisions should also consider disease stage, comorbidities, and patient preferences.

Original languageEnglish (US)
Pages (from-to)1134-1150
Number of pages17
JournalJournal of Clinical Oncology
Volume34
Issue number10
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

Fingerprint

Medical Oncology
Practice Guidelines
Biomarkers
Breast Neoplasms
Guidelines
Progesterone Receptors
Estrogen Receptors
Randomized Controlled Trials
Therapeutics
Patient Preference
Plasminogen Activators
Plasminogen Activator Inhibitor 1
Urokinase-Type Plasminogen Activator
Tumor Biomarkers
Disease-Free Survival
Observational Studies
Comorbidity
Retrospective Studies
Prospective Studies
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Use of biomarkers to guide decisions on adjuvant systemic therapy forwomenwith early-stage invasive breast cancer : American Society of clinical Oncology clinical practice guideline. / Harris, Lyndsay N.; Ismaila, Nofisat; McShane, Lisa M.; Andre, Fabrice; Collyar, Deborah E.; Gonzalez-Angulo, Ana M.; Hammond, Elizabeth H.; Kuderer, Nicole M.; Liu, Minetta C; Mennel, Robert G.; Van Poznak, Catherine; Bast, Robert C.; Hayes, Daniel F.

In: Journal of Clinical Oncology, Vol. 34, No. 10, 01.04.2016, p. 1134-1150.

Research output: Contribution to journalArticle

Harris, LN, Ismaila, N, McShane, LM, Andre, F, Collyar, DE, Gonzalez-Angulo, AM, Hammond, EH, Kuderer, NM, Liu, MC, Mennel, RG, Van Poznak, C, Bast, RC & Hayes, DF 2016, 'Use of biomarkers to guide decisions on adjuvant systemic therapy forwomenwith early-stage invasive breast cancer: American Society of clinical Oncology clinical practice guideline', Journal of Clinical Oncology, vol. 34, no. 10, pp. 1134-1150. https://doi.org/10.1200/JCO.2015.65.2289
Harris, Lyndsay N. ; Ismaila, Nofisat ; McShane, Lisa M. ; Andre, Fabrice ; Collyar, Deborah E. ; Gonzalez-Angulo, Ana M. ; Hammond, Elizabeth H. ; Kuderer, Nicole M. ; Liu, Minetta C ; Mennel, Robert G. ; Van Poznak, Catherine ; Bast, Robert C. ; Hayes, Daniel F. / Use of biomarkers to guide decisions on adjuvant systemic therapy forwomenwith early-stage invasive breast cancer : American Society of clinical Oncology clinical practice guideline. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 10. pp. 1134-1150.
@article{ba46c6aa343545008f07e20d687a879d,
title = "Use of biomarkers to guide decisions on adjuvant systemic therapy forwomenwith early-stage invasive breast cancer: American Society of clinical Oncology clinical practice guideline",
abstract = "Purpose: To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. Methods: A literature search and prospectively defined study selection sought systematic reviews, metaanalyses, randomized controlled trials, prospective-retrospective studies, and prospective comparative observational studies published from 2006 through 2014. Outcomes of interest included overall survival and disease-free or recurrence-free survival. Expert panel members used informal consensus to develop evidence-based guideline recommendations. Results: The literature search identified 50 relevant studies. One randomized clinical trial and 18 prospectiveretrospective studies were found to have evaluated the clinical utility, as defined by the guideline, of specific biomarkers for guiding decisions on the need for adjuvant systemic therapy. No studies that met guideline criteria for clinical utility were found to guide choice of specific treatments or regimens. Recommendations: In addition to estrogen and progesterone receptors and human epidermal growth factor receptor 2, the panel found sufficient evidence of clinical utility for the biomarker assays Oncotype DX, EndoPredict, PAM50, Breast Cancer Index, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgroups of breast cancer. No biomarker except for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 was found to guide choices of specific treatment regimens. Treatment decisions should also consider disease stage, comorbidities, and patient preferences.",
author = "Harris, {Lyndsay N.} and Nofisat Ismaila and McShane, {Lisa M.} and Fabrice Andre and Collyar, {Deborah E.} and Gonzalez-Angulo, {Ana M.} and Hammond, {Elizabeth H.} and Kuderer, {Nicole M.} and Liu, {Minetta C} and Mennel, {Robert G.} and {Van Poznak}, Catherine and Bast, {Robert C.} and Hayes, {Daniel F.}",
year = "2016",
month = "4",
day = "1",
doi = "10.1200/JCO.2015.65.2289",
language = "English (US)",
volume = "34",
pages = "1134--1150",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Use of biomarkers to guide decisions on adjuvant systemic therapy forwomenwith early-stage invasive breast cancer

T2 - American Society of clinical Oncology clinical practice guideline

AU - Harris, Lyndsay N.

AU - Ismaila, Nofisat

AU - McShane, Lisa M.

AU - Andre, Fabrice

AU - Collyar, Deborah E.

AU - Gonzalez-Angulo, Ana M.

AU - Hammond, Elizabeth H.

AU - Kuderer, Nicole M.

AU - Liu, Minetta C

AU - Mennel, Robert G.

AU - Van Poznak, Catherine

AU - Bast, Robert C.

AU - Hayes, Daniel F.

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose: To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. Methods: A literature search and prospectively defined study selection sought systematic reviews, metaanalyses, randomized controlled trials, prospective-retrospective studies, and prospective comparative observational studies published from 2006 through 2014. Outcomes of interest included overall survival and disease-free or recurrence-free survival. Expert panel members used informal consensus to develop evidence-based guideline recommendations. Results: The literature search identified 50 relevant studies. One randomized clinical trial and 18 prospectiveretrospective studies were found to have evaluated the clinical utility, as defined by the guideline, of specific biomarkers for guiding decisions on the need for adjuvant systemic therapy. No studies that met guideline criteria for clinical utility were found to guide choice of specific treatments or regimens. Recommendations: In addition to estrogen and progesterone receptors and human epidermal growth factor receptor 2, the panel found sufficient evidence of clinical utility for the biomarker assays Oncotype DX, EndoPredict, PAM50, Breast Cancer Index, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgroups of breast cancer. No biomarker except for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 was found to guide choices of specific treatment regimens. Treatment decisions should also consider disease stage, comorbidities, and patient preferences.

AB - Purpose: To provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. Methods: A literature search and prospectively defined study selection sought systematic reviews, metaanalyses, randomized controlled trials, prospective-retrospective studies, and prospective comparative observational studies published from 2006 through 2014. Outcomes of interest included overall survival and disease-free or recurrence-free survival. Expert panel members used informal consensus to develop evidence-based guideline recommendations. Results: The literature search identified 50 relevant studies. One randomized clinical trial and 18 prospectiveretrospective studies were found to have evaluated the clinical utility, as defined by the guideline, of specific biomarkers for guiding decisions on the need for adjuvant systemic therapy. No studies that met guideline criteria for clinical utility were found to guide choice of specific treatments or regimens. Recommendations: In addition to estrogen and progesterone receptors and human epidermal growth factor receptor 2, the panel found sufficient evidence of clinical utility for the biomarker assays Oncotype DX, EndoPredict, PAM50, Breast Cancer Index, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgroups of breast cancer. No biomarker except for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 was found to guide choices of specific treatment regimens. Treatment decisions should also consider disease stage, comorbidities, and patient preferences.

UR - http://www.scopus.com/inward/record.url?scp=84963558666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963558666&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.65.2289

DO - 10.1200/JCO.2015.65.2289

M3 - Article

C2 - 26858339

AN - SCOPUS:84963558666

VL - 34

SP - 1134

EP - 1150

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -